Enteric Coated Rabeprazole Sodium & Sustained Release Levosulpiride Capsules – Rabaval L Capsules

Rabaval L Capsules
Composition:- Enteric Coated Rabeprazole Sodium 20 mg & Sustained Release Levosulpiride 75 mg.

Rabaval L Capsules – This formulation of Enteric Coated Rabeprazole Sodium & Sustained Release Levosulpiride Capsules is a combination of Rabeprazole, a proton pump inhibitor (PPI), reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme, treats GERD, and aids in healing peptic ulcers and esophageal damage caused by excess acid; and Levosulpiride, a prokinetic agent, provides dual action by reducing stomach acid and improving gastrointestinal motility. It is highly effective in managing acid reflux, gastritis, and functional dyspepsia.
Marketed by: Wonne International Pvt. Ltd.

Key Points of Enteric Coated Rabeprazole Sodium & Sustained Release Levosulpiride Capsules – Rabaval L Capsules

• Dual Action Formula: Reduces stomach acid while enhancing gastric motility for better digestion
• More Effective than PPI Alone: Targets both acid suppression and gut motility, ensuring faster and more complete relief and reducing gastric irritation, nausea, and bloating in patients with chronic digestive issues.
• Broad symptom management: Effective in multiple conditions such as GERD, Indigestion, bloating, post-meal discomfort, IBS with Dyspepsia, and chronic gastritis.

• General Physician
• Gastroenterologist
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.